/
We are a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib or AF), left atrial appendage (LAA) management and post-operative pain management. Afib is an irregular heartbeat, or arrhythmia, which affects over 59 million people worldwide and is a growing epidemic.
The business is unprofitable at the operating level (-1.77% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 14.9% YoY with margins expanding 6.8pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$552M
▲ +14.9% YoY
Net Income (TTM)
-$5M
▲ +74.4% YoY
Op. Margin
-0.54%
▲ +6.8pp YoY
ROIC
-0.42%
▲ +4.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$54M
▲ +6381.1% YoY
Op. Cash Flow (TTM)
$64M
▲ +369.8% YoY
Net Debt
-$71M
Net Cash Position
Cash & Equiv.
$146M
5Y CAGR: +20.9%
Continue Research